Idenix Pharmaceuticals
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Idenix Pharmaceuticals - overview
Established
1998
Location
Cambridge, MA, US
Primary Industry
Pharmaceuticals
About
Idenix Pharmaceuticals, Inc. (f. k. a.
Novirio Pharmaceuticals Limited) is engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases.
Current Investors
MPM BioImpact
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.idenix.com
Verticals
HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Idenix Pharmaceuticals - financials
| Fiscal Year Ended | Dec 31, 2001 | Dec 31, 2002 | Dec 31, 2003 | Dec 31, 2004 | Dec 31, 2005 | Dec 31, 2006 | Dec 31, 2007 | Dec 31, 2008 | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 1,226,000 | - | - | 95,389,000 | 64,718,000 | 67,377,000 | 68,028,000 | 10,049,000 | 12,616,000 | 10,222,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | (32.2%) | 4.1% | 1.0% | (85.2%) | 25.5% | (19.0%) | - | - | - |
| EBITDA (USD) | (27,507,000) | - | - | (6,889,000) | (53,463,000) | (82,256,000) | (82,949,000) | (67,607,000) | (49,248,000) | (58,150,000) | - | - | - |
| Operating Income (USD) | (27,844,000) | - | - | (8,193,000) | (55,529,000) | (85,719,000) | (91,904,000) | (73,010,000) | (54,434,000) | (62,726,000) | - | - | - |
| Operating Margin | (2271.1%) | - | - | (8.6%) | (85.8%) | (127.2%) | (135.1%) | (726.5%) | (431.5%) | (613.6%) | - | - | - |
| % EBITDA Margin | (2243.6%) | - | - | (7.2%) | (82.6%) | (122.1%) | (121.9%) | (672.8%) | (390.4%) | (568.9%) | - | - | - |
| NET Income (USD) | (27,335,000) | - | - | (6,244,000) | (50,777,000) | (75,087,000) | (82,515,000) | (70,206,000) | (53,219,000) | (61,555,000) | - | - | - |
| % Net Margin | (2229.6%) | - | - | (6.5%) | (78.5%) | (111.4%) | (121.3%) | (698.6%) | (421.8%) | (602.2%) | - | - | - |
Idenix Pharmaceuticals - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.